Lung Cancer

Last Posted: Nov-18-2016 10AM

 Lung Cancer expanded expanded

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.
Garzón Mónica et al. Translational lung cancer research 2016 Oct 5(5) 511-516

Lung Cancer Awareness

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.
Hiley Crispin T et al. Lancet (London, England) 2016 Sep (10048) 1002-11

More information on this topic

Last Updated: Nov 16, 2016

• KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.
  Garzón Mónica et al. Translational lung cancer research 2016 Oct 5(5) 511-516
• The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
  Perea Francisco, et al. International journal of cancer 2016 10
• Lung Cancer Awareness 
• EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.
  Toki Maria I, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 11 (11) 1901-1911
• Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.
  Rosell Rafael, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 11 (11) 1954-1961
• Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer.
  Wang Yanwen, et al. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2016 10 1-23
• Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
  Huynh Tiffany G, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 11 (11) 1869-1878
• Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis.
  Kim Seong-Jin, et al. Journal of the National Cancer Institute 2017 3 (3)
• EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
  Zhao Jing, et al. Cancer chemotherapy and pharmacology 2016 10
• [Clinicopathologic Features and Prognostic Implications in 72 Cases ?with Lung Adenosquamous Carcinoma].
  Wu Xi, et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2016 10 (10) 653-658
• [Driven Gene in Patients with Lung Squamous Cell Carcinoma: ?Analysis of Clinicopathologic Characteristics and Prognosis].
  Zhang Tongtong, et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2016 10 (10) 648-652
• A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.
  Levy Antonin, et al. Oncotarget 2016 10
• Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
  Zhang Qiuyi, et al. Thoracic cancer 2016 9
• Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
  Han Ji-Youn, et al. BMC cancer 2016 10 (1) 803
• Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response.
  Park Ha Young, et al. Thoracic cancer 2016 9

• CDC Information (3)
• CDC-Authored Pub (8)

• Human (35)
• Pathogen (0)

• Human (4009)
• Pathogen (0)

• Human (65)
• Pathogen (0)

• Guidelines (8)
• Tier Table (4)
• Synthesis (11)

• Huamn (4)
• Pathogen (0)

Relevant Resources

• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB